• Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor
  • TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds
  • First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo
  • Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer
  • FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment
  • Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC
  • Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial
  • EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation
  • Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer
  • FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC
  • Fewer, Higher Doses of Radiation Therapy Safe for Early Breast Cancer
  • Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe